A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia
- 24 August 2013
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 163 (3), 393-399
- https://doi.org/10.1111/bjh.12541
Abstract
The impact of first‐line treatment with the anti‐CD 20 chimeric monoclonal antibody rituximab in patients with warm‐antibody reactive autoimmune haemolytic anaemia (WAIHA) is unknown. We report the first randomized study of 64 patients with newly diagnosed WAIHA who received prednisolone and rituximab combined (N = 32) or prednisolone monotherapy (N = 32). After 12 months, a satisfactory response was observed in 75% of the patients treated with rituximab and prednisolone but in a significantly smaller proportion (36%) of those given prednisolone alone (P = 0·003). Furthermore, relapse‐free survival was significantly better after the combined therapy than after prednisolone monotherapy (P = 0·02). After 36 months, about 70% of the patients were still in remission in the rituximab‐prednisolone group, whereas only about 45% were still in complete or partial remission in the prednisolone group. There was no significant difference between the two groups regarding adverse reactions to the studied medications. Likewise, serious adverse events were equally distributed, and no allergic reactions to rituximab were recorded. In conclusion, our data show that using rituximab and prednisolone combined rather than prednisolone alone as first‐line treatment in WAIHA increases both the rate and the duration of the response.Keywords
This publication has 23 references indexed in Scilit:
- Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studiesBlood, 2012
- A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopeniaBlood, 2012
- Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adultsBlood, 2011
- Rituximab in auto‐immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric studyJournal of Internal Medicine, 2009
- Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: Retrospective analysis of 27 casesAmerican Journal of Hematology, 2009
- Rituximab in the treatment of autoimmune haematological disordersBritish Journal of Haematology, 2008
- Rituximab for warm‐type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patientsEuropean Journal of Haematology, 2007
- Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patientsBlood, 2004
- Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemiaLeukemia, 2002
- Successful treatment of steroid and cyclophosphamide-resistant hemolysis in chronic lymphocytic leukemia with rituximabAmerican Journal of Hematology, 2002